Volume: 12 Issue: 1
Year: 2024, Page: 45-48, Doi: https://doi.org/10.47799/pimr.1201.09
Received: March 4, 2024 Accepted: March 30, 2025 Published: April 12, 2025
Introduction: Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder. Facial angiofibromas are the most common cutaneous findings of TSC. Treatment modalities such as laser, surgery, and/or cryotherapy are employed. Topical therapy with Sirolimus, an mTOR inhibitor, showed beneficial effects. Objective: To study the effects of topical sirolimus (0.1%) on Facial Angiofibromas in patients of TSC. Methodology : Four patients with facial angiofibromas were included. They applied Sirolimus preparation twice daily, for 3 months. The Facial Angiofibroma Severity Index (FASI) was recorded pre-intervention, at 3 months and after 6 months. Results: All the patients showed a reduction in the FASI score at the end of three months of therapy. In three patients, on discontinuing therapy, there was no change in the FASI score at the end of six months, i.e., FASI 3 and FASI 6 were the same. Conclusion: Topical sirolimus is an effective treatment for facial angiofibroma in patients with TSC.
Keywords: Facial Angiofibroma, Topical Sirolimus, Tuberous Sclerosis Complex
Cinar, Suhan Levent, Kartal, Derya, Bayram, Aysegul Kocak, Canpolat, Mehmet, Borlu, Murat, Ferahbas, Ayten & Per, Huseyin . 2017. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis. Indian J Dermatol Venereol Leprol 83(1):27–32.
Samanta, Debabrata . 2015. Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma. Indian J Dermatol Venereol Leprol 81(5):540–541.
Mustaqim, Khairul, Mohd Ghazi, Ahmad Fadzli Nizam, Harun Nor Rashid, Siti Aminah & Mohamad, Siti . 2023. Managing Different Spectrums of Tuberous Sclerosis Facial Angiofibroma: A Report of Two Cases. Cureus 15(2):e35200.
Hongal, AA, Aithal, SS & Revathi, TN . 2023. Facial Angiofibroma Severity Index: A beneficial tool to evaluate the treatment response of the skin of colour. Indian J Dermatol Venereol Leprol 89(1):130–132.
Koenig, Mary Kay, Bell, Cynthia S, Hebert, Adelaide A, Roberson, Jeffrey, Samuels, Julie A, Slopis, John M, Tate, Peter, Northrup, Hope & Collaborators, TREATMENT Trial . 2018. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial. JAMA Dermatol 154(7):773–780.
Vasani, Resham . 2018. Topical sirolimus in the treatment of facial angiofibromas. Indian J Drugs Dermatol 4:49–51.
©2024 (Leena HN) et al. This is an open-access journal, and arƟcles are distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.
HN L, Raghavan SB, HR Y, Sowmyanarayan S, Vittalrao AM, Hosthota A. Therapeutic effect of Topical Sirolimus on Facial Angiofibromas in Patients of Tuberous Sclerosis Complex. Perspectives in Medical Research. 2024;12(1):45-48 DOI: 10.47799/pimr.1201.09